Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Operating Cash Flow

Cash generated by the company's core business operations during the period.

Novartis AGNYSE: NVS

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow declines year over year

Q2 FY2026 operating cash flow of $5.89B fell 11.6% year over year, in line with the -11.5% change in trailing-twelve-month operating cash flow. Sequentially, it rose 60.2% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.

Context

  • Operating cash flow amounted to 35.1% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Operating cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -11.6% toward the trailing-twelve-month pace of -11.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.89B+60.2% QoQ
Last fiscal yearDec 2025
$19.24B+9.2% YoY
LTMJun 2026
$18.39B-11.5% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.6%——
1 year+9.2%——
3-year CAGR+10.6%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
19.24B USD
Year-over-year change
+9.2%
4-year CAGR
+6.3%

Operating Cash Flow vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.5% is the 8th highest of 11, against a peer median of +7.9%.
  • Operating cash flow amounts to 33.1% of revenue for NVS, versus a peer median of 27.8%.
NVS Competitors
Operating Cash Flow for NVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 133.01B DKK+9.4%+14.7%40.4%
JNJJohnson & JohnsonLTM Sep 2026$26.16B USD+8.1%+5.0%26.3%
MRKMerck & Co., Inc.LTM Jun 2026$19.97B USD+7.7%-4.8%30.1%
ABBVAbbVie Inc.LTM Jun 2026$19.51B USD+1.2%-8.6%30.3%
NVSNovartis AGLTM Jun 2026$18.39B USD-11.5%+10.6%33.1%
SNYSanofiLTM Jun 2026€14.29B EUR+582.9%+4.8%29.2%
GILDGilead Sciences, Inc.LTM Jun 2026$13.55B USD+37.3%+3.4%44.5%
PFEPfizer Inc.LTM Jun 2026$13.4B USD-11.8%-26.3%21.0%
AZNAstraZeneca PLCLTM Sep 2026$13.33B USD-11.9%+14.1%21.4%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$12.78B USD-19.6%+2.7%26.0%
GSKGSK plcLTM Jun 2026£8.74B GBP+13.2%-4.3%26.3%
Peer median (excluding NVS) —+7.9%+3.0%27.8%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income22.91B6.05B8.57B11.94B14.06B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
Deferred Income Tax1.63B1.13B551M1.7B(361.84M)
Stock-Based Compensation700M791M865M1.04B0
Change in Working Capital(73M)(796M)(369M)(706M)(3.08B)
Accounts Receivables(352M)(397M)(1.5B)(931M)(1.13B)
Inventory(102M)(560M)(546M)(225M)34.17M
Accounts Payables(111M)(181M)479M(105M)(274.4M)
Other Working Capital492M342M1.2B555M(1.71B)
Other Non-Cash Items(15.68B)359M(3.44B)(2.43B)3.27B
Operating Cash Flow15.07B14.24B14.46B17.62B19.24B
Capital Expenditures(2.56B)(2.24B)(2.75B)(3.81B)(1.56B)
Acquisitions (Net)20.46B(864M)(3.57B)(3.83B)(3.01B)
Purchases of Investments(16.59B)(34.81B)(747M)(3.65B)(304.55M)
Sales of Investments2.74B39.49B11.6B3.7B2.19B
Other Investing Activities(1.34B)(1.43B)(624M)(2.38B)140.72M
Investing Cash Flow4.21B1.47B5.6B(7.51B)(4.9B)
Debt Repayment(5.67B)(2.59B)(1.94B)4.39B2.72B
Common Stock Issued000027.14M
Common Stock Repurchased(3.06B)(10.65B)(8.72B)(8.33B)(9.26B)
Dividends Paid(7.37B)(7.51B)(7.26B)(7.62B)(7.86B)
Other Financing Activities(169M)181M3.63B(177M)(577.95M)
Financing Cash Flow(16.26B)(20.56B)(14.28B)(11.74B)(14.94B)
Effect of Forex Changes(266M)(32M)100M(298M)579.07M
Net Change in Cash2.75B(4.89B)5.88B(1.93B)(24M)
Free Cash Flow12.52B12B11.71B13.81B17.69B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.